Distribution of Neutrophils in Bronchial Mucosal Tissue in Asthma Patients Before and After 4 Weeks Treatment With AZD 5069

Asthma Clinical Trial

Official title:

An Explorative Investigation to Study the Relationship and Distribution of Neutrophils in Bronchial Mucosal Tissue, Induced Sputum and Blood After Administration of 45 mg BD AZD 5069 for 4 Weeks to Patients With Moderate Persistent Neutrophilic Asthma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01890148
• Other study ID #: D3551C00003
• Status: Completed
• Phase: Phase 1
• First received: June 17, 2013
• Last updated: January 28, 2016
• Start date: March 2014
• Est. completion date: August 2014

Study information

• Verified date: January 2016
• Source: AstraZeneca
• Contact: n/a
• Is FDA regulated: No
• Health authority: Germany: Federal Institute for Drugs and Medical Devices
• Study type: Interventional

Clinical Trial Summary

Distribution of neutrophils in bronchial mucosal tissue in asthma patients before and after 4 wk treatment with AZD 5069

Description:

The purpose is to investigate the bronchial tissue neutrophil counts and distribution in asthma patients after 4 week oral treatment with AZD 5069

Recruitment information / eligibility

• Status: Completed
• Enrollment: 13
• Est. completion date: August 2014
• Est. primary completion date: August 2014
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Male or female patients of Caucasian origin, aged between 18 to 65 years, inclusive, at the time informed consent is obtained.

2. Physician based (according to GINA 2011) diagnosis of asthma for at least 6 months prior to the date informed consent is obtained and confirmed by 1 of the detailed respiratory criteria stated in the CSP

3. Morning prebronchodilator (ie, after abstinence from short-acting and long-acting ß-agonist treatment for = 6 and = 12 hours, respectively) FEV1 of =70% of predicted normal (PN) for age, sex and height at enrolment

4. Increased number of neutrophils in induced sputum samples at baseline, with a relative neutrophil count of = 50% of total sputum cell count

5. Physician prescribed daily use of medium or high dose ICS (= fluticasone 250 µg to = 1.000 µg or the equivalent daily, as defined in GINA 2011; see CSP Appendix E) plus LABA.

Exclusion Criteria:

1. History of clinically relevant allergies or idiosyncrasies to AZD5069 or other investigational CXCR2 antagonists, or any inactive ingredient(s) of the IMP, or tool-substances (eg, salbutamol, local anaesthetics) used for the purpose of this study

2. History of severe asthma exacerbation requiring hospitalization within the last 12 months before screening.

3. Asthma exacerbation requiring a treatment course of systemic (ie, oral or parenteral) corticosteroids within the 3 months before screening or = 3 courses within the last 12 months before screening.

4. Moderate to severe airflow limitation (FEV1 <70% PN)

5. Any chronic lower respiratory disease other than asthma (see CSP for details) that, as judged by the Investigator or Medical Monitor, would interfere with the evaluation of the IMP or interpretation of patient safety or study results.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label

Related Conditions & MeSH terms

• Asthma

Intervention

Drug:
• AZD5069
oral BD administration of 45 mg AZD5069

Locations

Country	Name	City	State
Germany	Research Site	Grosshansdorf

Sponsors (1)

Lead Sponsor	Collaborator
AstraZeneca

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Summary for Change From Baseline of Mean Global Semi-quantitative Score Values for Neutrophils in Bronchial Biopsies	Change from baseline reflects the Week 4 value minus the baseline value. Baseline value is Day-14 measurement.; For semi-quantitative scores, 1= few number of Neutrophils, 2= moderate number of Neutrophils, 3= abundant of Neutrophils. For this end point the reduction in mean of semi-quantitative (arbitrary) scores indicates better result, i.e. lower numbers of Neutrophils.; The scores given for the biopsies taken at screening and end of treatment is the mean global semi-quantitative scores for the three compartments intraepithelial, subepithelial and submucosal.	Baseline and Week 4	No
Primary	Summary for Change From Baseline Neutrophils in Sputum	Change from Baseline reflects the Day 8, Day22 and Day29 minus the baseline value.	Baseline, Day 8, Day 22 and Day29	No
Primary	Summary for Change From Baseline Neutrophil Cell Counts in Blood	Change from Baseline reflects the Day 2, Day 8, Day 15, Day 22, Day29 and Day 34 minus the baseline value	Baseline, Day 2, Day 8, Day 15, Day 22, Day29 and Day 34	No
Secondary	Summary for Change From Baseline for IL-8 by Type of Sample	Change from baseline reflects the Day 29 value minus the baseline value.	Baseline and Day 29	No
Secondary	Summary for Change From Baseline for GRO-alpha by Type of Sample	Change from baseline reflects the Day 29 value minus the baseline value.	Baseline and Day 29	No
Secondary	Summary for Change From Baseline for MMP-9 by Type of Sample	Change from baseline reflects the Day 29 value minus the baseline value.	Baseline and Day 29	No
Secondary	Summary Statistics for AUC0-4hrs on Day 29/ Visit T7 (PK Analysis Set)	Summary statistics including geometric mean and standard error for AUC0-4hrs on Day 29/ Visit T7 (PK analysis set).; Plasma concentration data beyond 0.5 hrs post dose at Day 29 were missing for one patient. For this patient only Cmin value was reported and the AUC0-4hrs and Cmax values were not reported.	At 0, 0.5, 1, 1.5, 2, 2.5, 3, 4 hours post dose on Day 29 (Visit T7)	No
Secondary	Summary Statistics for Cmin on Day 29/ Visit T7 (PK Analysis Set)	Summary statistics including geometric mean and standard error for Cmin on Day 29/ Visit T7 (PK analysis set).; Plasma concentration data beyond 0.5 hrs post dose at Day 29 were missing for one patient. For this patient only Cmin value was reported and the AUC0-4hrs and Cmax values were not reported.	At 0, 0.5, 1, 1.5, 2, 2.5, 3, 4 hours post dose on Day 29 (Visit T7)	No
Secondary	Summary Statistics for Cmax on Day 29/ Visit T7 (PK Analysis Set)	Summary statistics including geometric mean and standard error for Cmax on Day 29/ Visit T7 (PK analysis set).; Plasma concentration data beyond 0.5 hrs post dose at Day 29 were missing for one patient. For this patient only Cmin value was reported and the AUC0-4hrs and Cmax values were not reported.	At 0, 0.5, 1, 1.5, 2, 2.5, 3, 4 hours post dose on Day 29 (Visit T7)	No
Secondary	Number of Adverse Events	Summary of number of adverse events (safety set)	Up to 40 days	Yes
Secondary	Number of Participants With Adverse Events	Summary of number of participants with adverse events (safety set)	Up to 40 days	Yes
Secondary	Summary Statistics for Patient Diary Variables (Day Time)	Summary statistics for patient diary variable, observations with no asthma symptoms (day time), by period (safety set).; The screening period was Day -14 to -1. Period 1 was the first half of treatment period, Day 1 to daytime record Day 15. Period 2 was the second half of treatment period, night-time record Day 15 to night-time record Day 29+1.; One participant left the study on day 2, due to adverse event.	Up to 44 days	No
Secondary	Summary Statistics for Patient Diary Variables (Night Time)	Summary statistics for patient diary variable, observations with no asthma symptoms (night time), by period (safety set).; The screening period was Day -14 to -1. Period 1 was the first half of treatment period, Day 1 to daytime record Day 15. Period 2 was the second half of treatment period, night-time record Day 15 to night-time record Day 29+1.; One participant left the study on day 2, due to adverse event.	Up to 44 days	No